09.07.2020 | Letter to the Editor
Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020
Einloggen, um Zugang zu erhalten